Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Human repeated insult patch test indicates upsalite is not a skin sensitiser.

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records
Reference
Endpoint:
skin sensitisation: in vivo (non-LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
22/05/2018 - 30/06/2018
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
test procedure in accordance with national standard methods
Qualifier:
according to guideline
Guideline:
other: Human Repeated Insult Patch Test (HRIPT)
Version / remarks:
The methodology used by the laboratory is an adaptation from that described by Marzulli and Maibach Human 'Repeated Insult Patch Test for delayed contact hypersensitivity: Marzulli F.N., Maibach H.I., Contact allergy : predictive testing in man, Contact Dermatitis, '1976, 2, pp. 1 -17.
GLP compliance:
yes
Type of study:
patch test
Justification for non-LLNA method:
No laboratory animal studies are available, but human experience indicates upsalite is not a skin sensitiser.
Specific details on test material used for the study:
Lot:Q0002-1701
Species:
other: human
Sex:
male/female
Details on test animals and environmental conditions:
The equipment used for the occluded patch is composed of a small plastic cavity of 0.64 cm 2 with a filter tissue at the bottom which is made to receive the product to test. All this is fixed to a hypoallergenic non woven adhesive tape.
Route:
epicutaneous, occlusive
Vehicle:
not specified
Concentration / amount:
The amount of test material applied to each patch 0.02ml
Day(s)/duration:
9 times on the same site over a period of 3 consecutive weeks
No.:
#1
Route:
epicutaneous, occlusive
Vehicle:
not specified
Concentration / amount:
0,02ml
Day(s)/duration:
a single application
No. of animals per dose:
50 volunteers
Details on study design:
A skin examination of the application site is performed by the dermatologist before the 1st product application of the
induction phase, after each patch removal, the application of the challenge and its removal.The area on which the patch is applied is previously cleaned up with demineralised water and dried with cellulose cotton wool tissue.
The patches are put on the back of the volunteer.

Treatment sites are assessed before the first application of test material (baseline) and after treatment at 30 minutes
after patch removal during the induction period.
After a rest period of 2 weeks a patch was applied on a previously unpatched and patched skin site. This site was evaluated
on 30 minutes, 24, 48, 72 and 96 hours after removal.
Skin reactions are scored throughout the test by the same experienced assessor who made the baseline assessment and
under the same lighting source, following a pre-defined irritation and sensitization scoring scales.
Challenge controls:
A "negative" control is a patch without any product, applied in the same conditions as the product to be tested:
 if the product is tested pure: empty patch.
 if the product is tested diluted: patch with 0.02ml of the solvent used (demineralised water or mineral oil).
Key result
Reading:
1st reading
Hours after challenge:
0.5
Group:
test chemical
Dose level:
0,02
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
2nd reading
Hours after challenge:
24
Group:
test chemical
Dose level:
0,02
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
other: 3rd reading
Hours after challenge:
48
Group:
test chemical
Dose level:
0,02
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
other: 4th reading
Hours after challenge:
72
Group:
test chemical
Dose level:
0,02
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
other: 5th reading
Hours after challenge:
96
Group:
test chemical
Dose level:
0,02
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
1st reading
Hours after challenge:
0.5
Group:
negative control
Dose level:
0
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
2nd reading
Hours after challenge:
24
Group:
negative control
Dose level:
0
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
other: 3rd reading
Hours after challenge:
48
Group:
negative control
Dose level:
0
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
other: 4th reading
Hours after challenge:
72
Group:
negative control
Dose level:
0
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.
Key result
Reading:
other: 5th reading
Hours after challenge:
96
Group:
negative control
Dose level:
0
No. with + reactions:
0
Total no. in group:
50
Clinical observations:
On 0 volunteers (0%) noticed slight erythema & dryness. In this clinical study there was no evidence of oedema.

Skin reactions are scored throughout the test by the same experienced assessor who made the baseline assessment and under the same lighting source, following a pre-defined irritation and sensitization scoring scales.

Interpretation of results:
GHS criteria not met
Conclusions:
Throughout the study, the product induced no reaction or irritation. The number of volunteers that presented an allergic reaction was 0 percent (0%).According to the experimental conditions of the study, the test product, can be considered as “Non Sensitizing”.
Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

Skin sensitisation to the substance is considered to be unlikely due to the inorganic nature of the substance.

The main constituent Magnesium carbonate is an inorganic ionic solid and is expected to partition strongly to water rather than organic media.

Justification for classification or non-classification

Throughout the study, the product induced no irritation. Skin sensitisation to upsalite is considered to be unlikely due to the inorganic nature of the substance limiting absorption through the skin too.